Currently, pathological classification combined with the status of molecular markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), delineates breast cancer into subtypes: luminal A, luminal B, basal-like, and HER2-enriched4. This evidence concerns the gene ESR1 and breast carcinoma.